Atacicept met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback